Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cryo-Cord is a cryopreserved, DMSO-free viable placental umbilical cord allograft developed by Royal Biologics for topical application to chronic non-healing wounds, including diabetic foot ulcers. The product is obtained from donated human umbilical cord tissue from healthy mothers undergoing cesarean section delivery, processed aseptically, and preserved with a proprietary cryoprotectant rather than dimethyl sulfoxide. Its intended therapeutic effect is as a soft tissue barrier and wound dressing that delivers structural extracellular matrix and native placental tissue components such as Wharton's Jelly, growth factors, cytokines, and endogenous viable cells to support tissue repair and wound healing. It is a human tissue biologic/allograft rather than a small-molecule or conventional pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cryo-Cord.